WASHINGTON DC (April 25, 2019) — The US Food and Drug Administration today announced the launch of a new education campaign to help Americans understand the important role they play in removing and properly disposing of unused prescription-opioids from their homes. This new initiative is part of the FDA’s continued efforts to address the nationwide opioid crisis and aims to help decrease unnecessary exposure to opioids and prevent new addiction.

WASHINGTON DC (April 9, 2019) — The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk-factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

WASHINGTON DC (April 3, 2019) — Today, the US Food and Drug Administration announced it is making available online the adverse event reports related to animal drugs and medical devices used in animals. The reports will go back 30 years.

WASHINGTON DC (April 2, 2019) — In recent years, we’ve seen a growing interest in the development of therapies and other FDA-regulated consumer products derived from cannabis (Cannabis sativa L.) and its components, including cannabidiol (CBD). This interest spans the range of product categories that the agency regulates.